Hosted by China Pharmaceutical Enterprise Management Associationand undertaken by Healthcare Executive and HEJUN Consulting Group, “The Sixth China’s Most Competitive Top 20 Listed Pharmaceutical Companies in China and the Top 10 Listed Pharmaceutical Companies with the Highest Investment Value in 2014” was announced a few days ago. Fosun Pharma was on the list, with the title of “Top 20 Most Competitive Listed Pharmaceutical Companies in China for 2014”.

The selection lasted for 5 months since its launch in March 2013, conducting financial analysis for 222 China’s pharmaceutical enterprises with annual sales revenue amounting over RMB100 million that listed on the stock exchanges of Shanghai, Shenzhen, Hong Kong, Singapore, New York and NASDAQ. Nine indicators including sales revenue, profit, total market value, sales growth, profit growth, market value growth, return on net assets, debt-to-asset ratio and current ratio were used as basis data to constitute industry dimension, management dimension, capital dimension, manager dimension and resource dimension.

Among the top 20 companies being evaluated, in terms of business scale of the listed pharmaceutical manufacturing companies, there are 16 companies exceeded RMB2 billion, 14 companies exceeded RMB3 billion, 11 companies exceeded RMB5 billion and 3 companies exceeded RMB10 billion respectively. In particular, revenue from principal business of Ha Yao was nearly RMB20 billion, reaching RMB17.663 billion. As a leading enterprise among listed retail pharmaceutical companies, Sinopharm achieved revenue from principal business of RMB135.787 billion.

In terms of revenue from principal business, most of the top 20 companies had higher growth rate than average rate of increase in pharmaceutical sector, among which, 13 companies recorded over 20%, 8 companies recorded over 30%, and 3 companies recorded over 50% of growth rate in principal business respectively. In particular, profit growth of CSPC Pharmaceutical Group reached 132.99%.

In terms of profitability, average return on assets of the top 20 companies reached 25.69%, among which, 15 companies achieved over 20% of return on assets. As a listed pharmaceutical service company, return on assets of Wuxi PharmaTech was 89.81%, ranked as the first among the top 20 most competitive companies.
Overlooking major sub-sectors covered by the top 20 most competitive companies, the number of enterprises engaged in Chinese patent drug and chemical agent were close, taking up 15 seats, while two seats were held by enterprises engaged in medical apparatus and instruments. Three enterprises engaged in health care products, CRO and biological agent and others respectively were selected.

By reviewing the six sessions of the most competitive listed pharmaceutical companies, it was not difficult to find that a group of leading companies with excellent qualifications, sound development and profound foundation were successively on the list of Top 20. In particular, Heng Rui Medicine, Kangmei Pharmaceutical, Tasly and Yunnan Baiyao were selected into the list for a successive six sessions; Dong-E E-jiao and Sino Biopharmaceutical were selected into the list for a successive five years, and Fosun Pharma, Sinopharm and Mindray Medical were selected on the list for a successive four years, which is a full testimony of the strong industrial competitiveness of these companies.

The “Top 10 Listed Pharmaceutical Companies with the Highest Investment Value in 2014” was announced at the same time, 10 companies including Heng Rui Medicine, Huadong Medicine and so forth were finally awarded upon recommendation and voting by industrial experts, senior medical security analysts, institutional investors and financial reporters of medical industry. Overviewing the results of the recent sessions, those listed pharmaceutical companies on the list shown fast growth and returned value for shareholders.

From 22 to 24 August this year, an event jointly hosted by the People’s Government of Taizhou Municipality and China Pharmaceutical Enterprise Management Association in Taizhou, Jiangsu, the event theme was “Challenges over Transformation and Industry Restructure”.

On the occasion, government officials in charge of medical industry, economists, and entrepreneurs in the first echelon of China’s pharmacy will have a joyous gathering to discuss the development of China’s pharmaceutical industry under the current environment.